Sobi will pay partner Apellis $275 million up front and $25 million in potential milestones to reduce its ex-U.S. royalty obligations on Empaveli.

Sobi's and CTI's filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

To report SUSPECTED ADVERSE REACTIONS, contact Sobi, Inc. at 1-866-773-5274 or FDA at 1-800-FDA-1088 or fda.gov/medwatch. Please see the full Prescribing Information for Doptelet.

Swedish Orphan Biovitrum AB, or Sobi, SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. Shares ...

The drug was the centerpiece of Sobi’s 2019 buy of Dova Pharmaceuticals for $915 million. In Dova's custody, the 2016-approved med generated just $3.5 million in the second quarter of 2019.